FindTrial
Sign In

The efficacy of droxidopa fot the patients with MAPT mutation and PSP evaluated by tau imaging.

The efficacy of droxidopa fot the patients with MAPT mutation and PSP evaluated by tau imaging. - The efficacy of droxidopa fot the patients with MAPT mutation and PSP evaluated by tau imaging.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030527
Enrollment
10
Registered
2018-01-04
Start date
2016-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with frontotemporal dementia harboring MAPT N279K and progressive supranuclear palsy-Richardson type.

Interventions

Patients with MAPT N279K mutation and progressive supranuclear palsy.

Sponsors

Juntendo University School of Medicine
Lead Sponsor
Brain Disorder Translational Research Team, Department of Functional Brain Imaging Research (DOFI), Clinical Research Cluster, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QS
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The patients has bee known to have MAPT N279K, and defined clinical diagnosis as progressive supuranuclear palsy.

Exclusion criteria

Exclusion criteria: Exclude the patients not defined the above criteria.

Design outcomes

Primary

MeasureTime frame
PBB3-PET, basic examinations of blood, urine, and cerebrospinal fluids. Metabolome, cognitive test, brain MRI, and SPECT.—

Countries

Japan

Contacts

Public ContactKenya Nishioka

Juntendo University School of Medicine Neurology

nishioka@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026